However, a phase III trial demonstrated that cilengitide in combination with standard temozolomide radiotherapy did not have better efficacy than conventional treatment in glioblastoma, particularly in tumors with methylated O6 -methylguanine-DNA methyltransferase (MGMT) promoters, and the use of cilengitide as a subunit antagonist of the integrins αvβ3 and αvβ5 is currently still controversial (Desgrosellier and Cheresh, 2010). This evidence concerns the gene MGMT and glioblastoma.